The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B.
Updated statement from Genentech on Hemlibra, March 28, 2018.
The screening kit was developed for broad utility for both laboratories seeking a standardized inhibitor assay for clinical management and multi-center clinical studies of patients with hemophilia A
NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab).
Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product.
The submission was based on positive results from a multi-stage clinical trial program which included more than 250 children and adults with hemophilia A worldwide
The medication is indicated for on-demand treatment and control of bleeding episodes.
Update: Shire has issued a new statement regarding the injunction.
In the past few weeks, we have received many inquiries regarding the scope of the injunction Shire is seeking in its lawsuit against Genentech/Roche.
Medscape recently launched a new education opportunity for healthcare providers.
BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car